KP-1461
From The Right Wiki
Jump to navigationJump to search
 | |
| Clinical data | |
|---|---|
| Drug class | Reverse transcriptase inhibitor |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C16H23N4O6 |
| Molar mass | 367.382 g·mol−1 |
| 3D model (JSmol) | |
KP-161 is an experimental antiviral drug being studied for the treatment of HIV/AIDS.[1] It belongs to the class of nucleoside reverse transcriptase inhibitors.[2] KP-1461 is a prodrug of the active antiviral agent KP-1212.[3]
References
- ↑ "KP-1461". AIDSinfo. U.S. Department of Health and Human Services. Archived from the original on 2019-08-11. Retrieved 2018-09-04.
- ↑ Harris K, Sergueev D, Reno J (December 2006). "The chemistry and biology of KP-1461, a selective nucleoside mutagen for HIV therapy". Retrovirology. 3 (Suppl 1): S13. doi:10.1186/1742-4690-3-S1-S13. PMC 1716920.
- ↑ "KP-1461". DrugBank. Canadian Institutes of Health Research.
 | This antiinfective drug article is a stub. You can help Wikipedia by expanding it. |